Regeneron Pharmaceuticals: Investor Deadline for Class Action Lawsuit Participation is Tomorrow
Purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock who experienced substantial losses between August 1, 2025, and May 15, 2026, have an opportunity to lead a class action lawsuit.
Investors who purchased or acquired common stock in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between August 1, 2025, and May 15, 2026, and suffered significant losses, have until tomorrow, Monday, September 14, 2026, to seek to be appointed as lead plaintiff in a class action lawsuit.
The lawsuit alleges that Regeneron and certain of its executives violated federal securities laws. The claims center on allegedly false or misleading statements made by the company during the class period regarding its business operations and financial outlook.
Plaintiffs contend that these alleged misrepresentations inflated the company's stock price artificially. When the true nature of the company's situation became apparent, investors reportedly incurred substantial financial losses.
Law firm Robbins Geller Rudman & Dowd LLP announced the deadline for interested investors. The firm stated that details and instructions for potential lead plaintiffs can be found on their website.